Summary:
- This article reports the results of a clinical trial studying a new treatment for COVID-19 using a monoclonal antibody called bebtelovimab.
- The study found that bebtelovimab was effective in reducing the risk of hospitalization or death in high-risk adults with COVID-19, compared to a placebo.
- The findings suggest that bebtelovimab could be a valuable addition to the available treatment options for COVID-19, particularly for patients at high risk of severe illness.